Although this study was focused solely on identifying enzalutamide resistance mechanisms linked to CHD1 loss, it is remarkable that all four of the TFs identified have been previously implicated in advanced prostate cancer progression. The gene discussed is CHD1; the disease is Familial prostate cancer.